4/27
11:23 am
ogn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
Low
Report
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
4/27
11:02 am
ogn
Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical
Low
Report
Johnson Fistel Investigates Potential Breaches of Fiduciary Duty in Connection with the Proposed Acquisition of Organon by Sun Pharmaceutical
4/27
10:43 am
ogn
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Organon & Co. (NYSE: OGN)
Low
Report
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Organon & Co. (NYSE: OGN)
4/27
09:53 am
ogn
Organon (OGN) Soars 30.9%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Low
Report
Organon (OGN) Soars 30.9%: Is Further Upside Left in the Stock? [Yahoo! Finance]
4/27
08:20 am
ogn
OGN Stock Alert: Halper Sadeh LLC is Investigating Whether Organon & Co. is Obtaining a Fair Price for its Shareholders
Low
Report
OGN Stock Alert: Halper Sadeh LLC is Investigating Whether Organon & Co. is Obtaining a Fair Price for its Shareholders
4/27
02:23 am
ogn
Shareholder Alert: Ademi LLP investigates whether Organon & Co. is obtaining a Fair Price for Public Shareholders
High
Report
Shareholder Alert: Ademi LLP investigates whether Organon & Co. is obtaining a Fair Price for Public Shareholders
4/26
10:15 pm
ogn
Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal [CNBC]
High
Report
Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal [CNBC]
4/26
08:03 pm
ogn
Sun Pharma signs Definitive Agreement to Acquire Organon [Yahoo! Finance]
High
Report
Sun Pharma signs Definitive Agreement to Acquire Organon [Yahoo! Finance]
4/26
07:51 pm
ogn
Sun Pharma signs Definitive Agreement to Acquire Organon
High
Report
Sun Pharma signs Definitive Agreement to Acquire Organon
4/16
04:40 pm
ogn
The 10 Healthcare stocks with the lowest forward P/E ratios [Seeking Alpha]
Medium
Report
The 10 Healthcare stocks with the lowest forward P/E ratios [Seeking Alpha]
4/16
07:30 am
ogn
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
Medium
Report
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
4/16
06:14 am
ogn
Organon & Co. (OGN) was upgraded by Zacks Research from "strong sell" to "hold".
Medium
Report
Organon & Co. (OGN) was upgraded by Zacks Research from "strong sell" to "hold".
4/16
03:43 am
ogn
Why Organon (OGN) Is Surging as Buyout Interest Gains Traction [Yahoo! Finance]
Medium
Report
Why Organon (OGN) Is Surging as Buyout Interest Gains Traction [Yahoo! Finance]
4/15
07:30 am
ogn
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
Medium
Report
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
3/29
06:31 pm
ogn
Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants
Medium
Report
Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants
3/27
08:00 am
ogn
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
Medium
Report
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
3/18
01:26 pm
ogn
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility [Seeking Alpha]
Low
Report
Organon leads ultra-low P/E stocks at 1.8x as small-cap stocks face volatility [Seeking Alpha]
2/27
08:00 am
ogn
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
Low
Report
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
2/24
09:41 am
ogn
Organon & Co. (NYSE:OGN) had its price target raised by analysts at Barclays PLC from $7.50 to $8.00. They now have an "underweight" rating on the stock.
Low
Report
Organon & Co. (NYSE:OGN) had its price target raised by analysts at Barclays PLC from $7.50 to $8.00. They now have an "underweight" rating on the stock.
2/23
04:55 pm
ogn
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% [Yahoo! Finance]
Medium
Report
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7% [Yahoo! Finance]
2/23
07:30 am
ogn
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
Low
Report
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
2/13
10:30 pm
ogn
Organon & Co. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Organon & Co. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/13
01:38 am
ogn
Organon & Co. Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Organon & Co. Q4 Earnings Call Highlights [Yahoo! Finance]
2/12
08:05 am
ogn
Organon in charts: Q4 revenue from Women's Health and Established Brands down; Biosimilars up Y/Y [Seeking Alpha]
Neutral
Report
Organon in charts: Q4 revenue from Women's Health and Established Brands down; Biosimilars up Y/Y [Seeking Alpha]
2/12
07:58 am
ogn
Earnings Snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook [Seeking Alpha]
Medium
Report
Earnings Snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook [Seeking Alpha]